This FDA paper from July 2020 makes some very interesting points about mRNA vaccines
"Replacing rare codons with those used more frequently does not always produce the desired effects" europepmc.org/article/med/32…
"For example if translation is too rapid, the protein might not fold correctly into a functional antigen, and this can have the undesired consequences of reducing
vaccine efficacy"
Dec 15, 2021 • 14 tweets • 6 min read
PNAS 2012: "In certain cases mass vaccination can have the counterproductive effect of allowing an increase in severe disease, through reducing opportunities for immunity to be boosted through natural exposure to infection"
This is almost prophetic
pnas.org/content/109/49…
"Even booster schedules do not offer a reliable means of maintaining herd immunity. On the other hand, boosting may instead be supplied through natural exposure to infection, in which case vaccination may in fact reduce existing herd immunity."
Oct 9, 2021 • 26 tweets • 15 min read
Sinovac, Universidad Católica, Corrupción y Conflictos de Interés durante el proceso que determinó la elección del ensayo clínico con la vacuna SINOVAC.Este hilo profundiza un hilo anterior sobre la distribución d la vacuna SINOVAC.
¿Hay solo un interés sanitario en todo esto?
Para la determinación y autorización de una vacuna en Chile normalmente el @ministeriosalud trabaja en coordinación con:
- Comité Asesor en Vacunas y Estrategias de Inmunización (CAVEI)
- Programa Nacional de Inmunizaciones (PNI)
- Instituto de Salud Pública @ispch (ISP)
Oct 6, 2021 • 6 tweets • 4 min read
Nature 2005: "Caution raised over SARS vaccine"
"Jab against one strain might worsen infection with others." nature.com/articles/news0…
"A cautionary note has been sounded for those developing vaccines against severe acute respiratory syndrome (SARS). Some vaccines could prove useless against certain strains, or even worsen the infection, a preliminary study suggests."
Oct 2, 2021 • 27 tweets • 9 min read
Este hilo resume los problemas de seguridad y problemas a los que se ha visto enfrentada por 18 años la vacuna de virus inactivado contra el Sars Cov1, Mers y ahora Sars Cov2,ampliamente distribuida por SINOPHARM en muchos países latinoamericanos. ¿Qué tanto se ha avanzado?
Desde la aparición del SARS en 2003 las vacunas inactivadas fueron la 1° opción d desarrollo, pero desde el comienzo demostraron tener problemas serios de seguridad.
Los cuales posiblemente estén ocurriendo hoy en día.
Durante el hilo, observe la progresión d los años.
Oct 2, 2021 • 6 tweets • 1 min read
13 May 2013: SARS-Like Virus Vaccine Unlikely, Experts Say
"Health officials said vaccines were unlikely to play a role in controlling the outbreak"
"The thing that really takes time is the regulation aspect of it," said Ksiazek, professor in the dept. of pathology at the Univ. of Texas Medical Branch, describing the lengthy process of proving safety and efficacy in animal models before even thinking about testing in humans."
Oct 1, 2021 • 13 tweets • 4 min read
SARS vaccines: where are we?
"Data regarding the correlates of protection, animal models and the available evidence regarding potential vaccine ENHANCEMENT of SARS disease are discussed"
Inactivated virus vaccines
"However, despite high neutralizing antibody titers, protection was incomplete for all vaccine preparations and administration routes tested." 🤔@juancarlossaid
